Skip to content

PROVECTUS BIOPHARMACEUTICALS, INC.: 10-Q filed 2022-08-11

What PROVECTUS BIOPHARMACEUTICALS, INC. reported in its quarterly report filed 2022-08-11 (fiscal Q2 2022): 30 published measures, 83 facts as tagged in accession 0001493152-22-022049.

This filing

Form
10-Q (quarterly report)
Filed
2022-08-11
Fiscal period
fiscal Q2 2022
Accession
0001493152-22-022049 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PROVECTUS BIOPHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2022-06-302,443,409USD
At 2021-12-313,513,356USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2022-06-308,590,496USD
At 2021-12-317,700,636USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2022-06-30-6,147,087USD
At 2022-03-31-5,068,918USD
At 2021-12-31-4,187,280USD
At 2021-06-30-2,610,682USD
At 2021-03-31-31,615,870USD
At 2020-12-31-30,206,357USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2022-06-3084,274USD
At 2021-12-31682,984USD
At 2021-06-3047,407USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-1,077,841USD91
2022-01-01 to 2022-06-30-2,108,763USD181
2022-01-01 to 2022-03-31-1,030,922USD90
2021-04-01 to 2021-06-30-1,579,591USD91
2021-01-01 to 2021-06-30-3,249,541USD181
2021-01-01 to 2021-03-31-1,669,950USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2022-01-01 to 2022-06-30-1,470,104USD181
2021-01-01 to 2021-06-30-1,819,619USD181

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2022-04-01 to 2022-06-30321,710USD91
2022-01-01 to 2022-06-30509,315USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2022-01-01 to 2022-06-30396,815USD181
2021-01-01 to 2021-06-301,769,725USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2022-06-30-248,142,721USD
At 2021-12-31-246,033,958USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2022-04-01 to 2022-06-30419,447,119shares91
2022-01-01 to 2022-06-30419,447,119shares181
2021-04-01 to 2021-06-30403,628,466shares91
2021-01-01 to 2021-06-30402,910,628shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2022-04-01 to 2022-06-300USD/shares91
2022-01-01 to 2022-06-30-0.01USD/shares181
2021-04-01 to 2021-06-300USD/shares91
2021-01-01 to 2021-06-30-0.01USD/shares181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2022-06-3025,799USD
At 2021-12-3131,836USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2021-01-01 to 2021-06-3021,913USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-1,077,980USD91
2022-01-01 to 2022-06-30-2,078,038USD181
2021-04-01 to 2021-06-30-1,222,017USD91
2021-01-01 to 2021-06-30-2,402,693USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2022-06-302,278,747USD
At 2021-12-313,441,957USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2022-06-308,494,295USD
At 2021-12-317,700,636USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2022-06-301,894,201USD
At 2021-12-311,287,459USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2022-04-01 to 2022-06-301,399,690USD91
2022-01-01 to 2022-06-302,587,353USD181
2021-04-01 to 2021-06-301,222,017USD91
2021-01-01 to 2021-06-302,402,693USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2022-04-01 to 2022-06-30816,648USD91
2022-01-01 to 2022-06-301,487,764USD181
2021-04-01 to 2021-06-30602,979USD91
2021-01-01 to 2021-06-301,258,123USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2022-06-30419,447,119shares
At 2021-12-31419,447,119shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2022-06-30241,590,054USD
At 2021-12-31241,440,106USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2022-06-30-35,511USD
At 2021-12-31-34,467USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2022-06-30138,863USD
At 2021-12-3139,563USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2022-06-30138,863USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2022-06-3097,215USD
At 2021-12-3191,178USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-1,078,169USD91
2022-01-01 to 2022-06-30-2,109,807USD181
2021-04-01 to 2021-06-30-1,580,712USD91
2021-01-01 to 2021-06-30-3,249,825USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2022-04-01 to 2022-06-30583,042USD91
2022-01-01 to 2022-06-301,099,589USD181
2021-04-01 to 2021-06-30619,038USD91
2021-01-01 to 2021-06-301,144,570USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2022-01-01 to 2022-06-306,037USD181
2021-01-01 to 2021-06-306,432USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2022-04-01 to 2022-06-30139USD91
2022-01-01 to 2022-06-30-30,725USD181
2021-04-01 to 2021-06-30-357,574USD91
2021-01-01 to 2021-06-30-846,848USD181

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2022-01-01 to 2022-06-3038,625USD181
2021-01-01 to 2021-06-3045,784USD181

Inspect the source

Entity
PROVECTUS BIOPHARMACEUTICALS, INC. / CIK 0000315545
Captured
2026-09-19T14:56:22.911Z
SEC response SHA-256
5c46f06a9f23badc21fb49ef63f53fb89ac39f7570babcbf8a64cddf67fb05d2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000315545.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))